ReportWire

Tag: effective treatment

  • Hypnosis Could Work Wonders on IBS

    Hypnosis Could Work Wonders on IBS

    The change in Zack Rogers was sudden. In the middle of his 12th birthday party, his stomach started hurting. He went to bed early that night, missing much of his own slumber party, and then stayed home from school the whole next week. The stomach pain was excruciating, and he couldn’t keep any food down. He lost 40 pounds in just a few weeks.

    Zack spent the next three years in and out of hospitals and trying medicines that didn’t seem to work. His doctors eventually told the family that they had only one option: surgery to remove large parts of his damaged colon. But Zack’s mom, Angela Rogers, wasn’t on board. She had lost faith in his medical team and feared such an invasive step, so she asked another gastroenterologist for a second opinion. The new doctor suggested that Zack try one last treatment before surgery: hypnotherapy, in which a clinical professional helps a patient become deeply focused and relaxed in order to change their patterns of thinking.

    This time, the change was gradual, but no less dramatic. In the evening after his first hypnotherapy session, Zack felt nauseated but kept his dinner down. Over the next few weeks, he stopped throwing up in school and regained the stamina to play basketball and go for bike rides. Today, Zack is a freshman in college, living away from home—something he wouldn’t have thought was possible before he was hypnotized. “If I never did hypnosis,” he told me, “I would be a complete mess. I genuinely don’t know where I would be.”

    As far-fetched as it may seem, science supports the idea that digestive disorders can be treated with psychological interventions, including hypnosis. Research dating back to the 1980s suggests that, at least in the short term, hypnotherapy can be an effective treatment for irritable bowel syndrome, a gut disorder characterized by painful gastrointestinal symptoms but no visible damage to the gut. Now scientists are investigating whether it might also bring relief to patients with inflammatory bowel disease, who, like Zack, have observable damage to their digestive tract.

    Although hypnosis is a powerful relaxation tool on its own, in clinical settings, it’s most often combined with other, better-studied psychotherapy techniques, such as cognitive behavioral therapy. Research suggests that CBT, which is commonly used to treat conditions such as depression and anxiety, can also be helpful in the treatment of gastrointestinal disorders.

    Unlike CBT, hypnosis retains a reputation for quackery, and is regularly portrayed in pop culture and stage shows as a tool for exercising control over participants—willing or otherwise. And some practitioners do use it for debunked treatments, including recovered memory therapy. But whether hypnotherapy is legitimized as a medical tool has real stakes. Hypnosis practitioners believe—and there’s some research to back this up—that the technique may amplify the effectiveness of more well-established psychological interventions and therefore has the potential to provide rare benefit to patients

    Hypnosis has a long history as a pain reliever. In the first half of the 19th century, before anesthetics were widely available, some surgeons hypnotized their patients. Even today, hypnosis proponents claim that it may be an effective alternative treatment for chronic back pain and the stress of childbirth; a growing body of research suggests that hypnosis can be a cost-effective and side-effect free analgesic for some people with chronic pain, though good clinical data are hard to come by.

    The first randomized controlled trial of hypnotherapy for IBS was published in 1984. Among the participants—a small group of mostly female patients with severe, treatment-resistant disease— those who received hypnotherapy showed greater improvements in abdominal pain, bloating, and bowel function than those who received psychotherapy plus a placebo medication. A 2014 meta-analysis found that about half of IBS patients who try hypnotherapy see at least short-term improvements in their symptoms.

    The evidence for hypnotherapy isn’t as robust in the treatment of IBD, which is really an umbrella term for ulcerative colitis (Zack’s diagnosis) and Crohn’s disease. But there’s reason to believe that hypnosis could yield similar success in addressing symptoms of those conditions. The line between IBD and IBS can be murky; more than a quarter of IBD patients in remission have IBS as well. And although the evidence is still mixed—a study published in 2021, for example, found no difference in treatment outcomes between standard medical treatments and hypnotherapy—some early evidence suggests that hypnotherapy can also reduce inflammation in patients with ulcerative colitis. One small study found that just one session of hypnotherapy reduced ulcerative-colitis patients’ blood levels of several inflammatory markers.

    Perhaps most important, a large body of research shows a strong link between cognition and digestion. Millions of neurons, collectively known as the enteric nervous system, regulate our digestion and are in constant communication with the central nervous system. This connection, called the “brain-gut axis,” may be why we feel so many emotions in our gut, whether the butterflies of anxiety or the clench of anger. It might also explain why both anxiety and depression are more common among patients with IBD compared with the general population. “Unequivocally, stress plays a major role in any digestive disease,” Gary Lichtenstein, a gastroenterology professor and the director of the Inflammatory Bowel Disease Center at the Hospital of the University of Pennsylvania, told me.

    When this brain-gut axis gets out of whack, it’s known to worsen some digestive disorders. In patients with gastrointestinal issues, the tissues in the gut can become hypersensitive over time. The brain learns to interpret signals from the gut, including normal functioning, as discomfort. This faulty communication results in what experts now call disorders of gut-brain interaction (DGBIs), which include IBS, functional dyspepsia, and other digestive disorders (but not IBD). Hypnosis, proponents say, can help patients rewire the cognitive-digestive connection. In many IBS and IBD cases, “we know there’s a mind-gut connection that can only be helped by a mental-health expert,” says Mark Mattar, a gastroenterologist and director of the IBD center at MedStar Georgetown University Hospital.

    Mattar works closely with Ali Navidi, the clinical psychologist to whom Zack was referred in 2020. Navidi told me that at his practice, GI Psychology, 83 percent of patients with DGBIs who complete at least 10 hypnotherapy sessions achieve their treatment goals, which usually amount to reducing pain, bloating, and other uncomfortable symptoms enough to go about their day-to-day life. His data are unpublished but in line with other studies on IBS showing that more than 80 percent of patients who get gut-directed hypnotherapy as part of their treatment plan experience improvements in pain and other GI symptoms. Those numbers are even higher among children and adolescents.

    Such findings persuaded the American College of Gastroenterology to recommend gut-directed psychotherapies—including hypnosis and CBT—for the treatment of IBS symptoms in its 2021 guidelines. Still, even among IBS patients, they’re not commonly used. No one appears to have studied the popularity of hypnosis specifically among IBS patients, but a 2017 study found that only 15 percent of people diagnosed with IBS had ever pursued “psychological therapies” of any kind.

    For many patients who follow through with hypnotherapy, the experience is not what they expect. Patients may conflate clinical hypnosis with entertainment hypnosis, where subjects quack like a duck or forget their own name. But at practices like Navidi’s, the therapist instead focuses on helping the patient enter a trance state—the same type of consciousness we all experience when we lose track of time working, scrolling Instagram, or driving and suddenly arriving at our destination. “When we’re in a trance, we have this intense, focused concentration, and that can be used in powerful ways,” Navidi said.

    Once the patient is in a trance state, therapists use guided imagery and suggestion to target specific gastrointestinal symptoms. “People get into a very relaxed state, and in that state I start to make suggestions about how the brain and the gut can work together better,” Jessica Gerson, a psychologist at NYU Langone’s Inflammatory Bowel Disease Center, told me. Gerson instructs her IBD patients to imagine the lining of their intestines healing. During his trance states, Zack was able to envision a control room for his pain in which he could dial knobs up and down. “I could turn the stomach pain down to a one or a zero, and it would go away,” Zack recalled recently, a note of surprise still in his voice.

    Many patients initially fear that during hypnosis they are ceding control of their mind and body to the hypnotherapist, Gerson told me. But patients are always “totally conscious, totally in control.” Indeed, Navidi and Gerson use this trance state to show patients exactly how much control they have over their own body. “Having a sense of agency is therapeutic,” Gerson said.

    These days, many gastroenterologists see psychotherapies like hypnosis as an important part of a holistic treatment plan—even for IBD. (IBD patients who do respond to hypnotherapy are likely to continue to need medical monitoring and interventions, Lichtenstein said.) While gut-directed hypnotherapy still hasn’t been proved to help IBD patients without co-occurring IBS symptoms, there’s not much of a downside to trying. The experts I spoke with agreed that hypnosis is relatively risk-free as long as it is administered by a clinician, patients continue to be monitored by their medical doctors, and therapists screen potential patients for severe mental illness and untreated trauma. Patients, too, need to consider whether they can afford hypnotherapy. Like many mental-health services, it’s not always covered by insurance. Zack’s sessions were $265 each out of pocket, but according to Angela, “it was worth every cent and then some.”

    Zack remembers getting stressed out a lot as a kid—over grades, making friends, basketball games, or nothing in particular. He credits Navidi with alleviating not only his stomach pain but also the relentless anxiety; he still uses the relaxation techniques he learned from Navidi when he gets worried about school or a basketball game.

    Zack is still on medication for his ulcerative colitis; every eight weeks he has an injection of Stelara, a medication that works by blocking inflammatory proteins. But after two years of appointments with Navidi, for the first time since his 12th birthday, his symptoms are reliably under control—and stress doesn’t make them come roaring back. He hasn’t had a flare up in about a year and a half. Most days, he doesn’t think about his diagnosis at all.

    Kate Wheeling

    Source link

  • Is This Premenstrual Condition a Mental Illness or Oppression?

    Is This Premenstrual Condition a Mental Illness or Oppression?

    This article originally appeared in Undark Magazine.

    For one week of every month, I have a very bad time. My back aches so badly I struggle to stand up straight. My mood swings from frantic to bleak. My concentration flags; it’s difficult to send an email. Then, my period starts, and the curse is lifted. I feel okay again.

    Like some 1 to 7 percent of menstruating women, I meet the criteria for premenstrual dysphoric disorder, or PMDD. According to the most recent edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR), a person with PMDD experiences marked emotional changes—such as sadness, anger, or anxiety—and physical or behavioral changes—such as difficulty concentrating, fatigue, or joint pain—in the week before their period. PMDD can also affect trans men and nonbinary people who menstruate.

    When I first heard of PMDD, it was a revelation. Here was a concrete explanation for the pain and stress I was feeling every month. Better yet, there was a simple, effective treatment: common antidepressant drugs called selective serotonin reuptake inhibitors, or SSRIs, which can be prescribed for people to take only in the two weeks before their period. Birth-control pills, cognitive behavioral therapy, and calcium supplements may also help.

    Then I heard about the controversy surrounding the diagnosis. When the American Psychiatric Association added a form of PMDD as a proposed disorder to the diagnostic manual in the 1980s—DSM-III-R—some scholars pushed back. They saw the diagnosis as part of the historical oppression of women, done in the name of mental health. The controversy reared up again as PMDD remained in the 1994 DSM-IV, where it was also listed under “Depressive Disorder Not Otherwise Specified.” Many people who menstruate experience emotional changes during their cycles, so defining it as a mental illness could have serious personal and societal consequences, critics argued. A 2002 Monitor on Psychology article, “Is PMDD real?,” quoted the late psychologist and author Paula Caplan: “Women are supposed to be cheerleaders,” she said. “When a woman is anything but that, she and her family are quick to think something is wrong.”

    In the end, the APA weighed these concerns and pushed ahead, adding PMDD to the DSM-5 as an official diagnosis in 2013. But I found the criticism disquieting. Had I embraced a modern hysteria diagnosis? Were the symptoms I experienced even real?

    Researchers have looked for hormonal differences between people who experience severe premenstrual distress and people who don’t. In some cases, they’ve found them: A 2021 meta-analysis found that people with PMDD tend to have lower levels of estradiol, a form of estrogen, between ovulation and menstruation. But other studies have shown little to no difference in hormone levels. “There are no biomarkers. There’s no test that can be done which helps identify someone with PMDD,” says Lynsay Matthews, who researches PMDD at University of the West of Scotland.

    Instead, to receive treatment, people experiencing premenstrual distress have to monitor their own mind and body. PMDD diagnosis is based on a symptom diary kept over the course of multiple menstrual cycles.

    The symptoms recorded in those diaries can be severe. In a 2022 survey, 34 percent of people with PMDD reported a past suicide attempt. More than half reported self-harm. “If someone has suicidal ideation or self-harm, or suicide attempts every month for 30 years, that wouldn’t be described as a normal female response to the menstrual cycle,” Matthews says.

    There is evidence that SSRIs work for people with PMDD, in ways researchers don’t fully understand. “In some cases, hours after taking an effective SSRI, people can feel a lot better,” Matthews says, referring to PMDD patients. In contrast, people with depression usually need to take SSRIs for weeks before feeling the effects. Researchers know the drugs’ mechanism of action is different for PMDD—they just don’t know why. “When people find that out, they find it quite validating that it is a medical condition,” Matthews says.

    Tamara Kayali Browne, a bioethicist at Deakin University, in Australia, agrees that some people experience serious distress in the week before their period—but disagrees with calling it a mental illness.

    “The crux of the problem seems to be that we are in a patriarchal society that treats women very differently and puts a lot of women under a lot of significant, disproportionate stress,” Browne says. That disproportionate stress begins early. Eighty-three percent of a sample of Australian PMDD patients reported trauma in early life. It continues in adulthood. A Swedish survey of 1,239 people with PMDD found that raising children was associated with higher rates of premenstrual distress.

    Between ovulation and menstruation, many people experience higher physical and emotional sensitivity. They may feel unwilling or unable to deal with the stressors they tolerate the rest of the month: the screaming baby, the messy partner. “Is it the time of the month where the truth comes out?” Browne suggests. Seen in this light, irritability, anxiety, and low mood are understandable reactions to life stressors, not symptoms of mental illness.

    There is a long history of doctors labeling women crazy. There is also a long history of doctors dismissing women’s pain. Debates about premenstrual distress are caught in the middle.

    When critics question PMDD and the less severe premenstrual syndrome, it can feel invalidating. “It’s time to stop questioning whether women’s experiences are real and instead start making them real priorities,” the journalists Emily Crockett and Julia Belluz wrote in response to an article that suggested PMS is culturally constructed.

    At the same time, when left unchecked, casual sexism can seep into the medical discourse around PMDD. Early pharmaceutical advertisements marketing SSRIs for PMDD show how this works in practice. In 2000, Eli Lilly packaged fluoxetine hydrochloride in a pink-and-purple capsule and branded it Sarafem. Advertisements for the drug featured incapable, unreasonable women; one fights a shopping cart, another bickers with her (male) partner. “Think it’s PMS? Think again. It could be PMDD.” (The Sarafem brand has since been discontinued.)

    What if we can question the structural factors that make life harder for women while providing medical support for people who are suffering? Could the critiques lead us to more, not fewer, options for people with PMDD?

    Medical interventions can be lifesaving for people with PMDD. But they don’t address a society that places a heavy burden on the shoulders of people assigned female at birth.

    Browne compares severe premenstrual distress to a broken leg. “If you have a broken leg, you really do need painkillers, because you’re experiencing pain,” she says. “But it’s not going to be helpful in the long term if you don’t deal with whatever the underlying cause is.” In the week before menstruation, the life stressors a person with PMDD deals with the rest of the month can feel unbearable. Those life stressors can and should be addressed alongside conventional medical treatment.

    One common stressor is the caregiving load. “Parenting is not only a massive trigger, but it’s also the biggest burden or the biggest guilt that comes with having PMDD,” Matthews says. “Not only are you struggling yourself every month, but you also feel as though you’re failing your children every month.” The co-parent can help alleviate this burden. When fathers spend more time with their kids—and doing child-related chores—mothers tend to be less stressed about parenting.

    Another stressor is relationship difficulties. The emotional changes that come with the premenstrual phase can make conflict with a partner more likely. They can also prompt the PMDD sufferer’s partner to dismiss those feelings. “Nowadays, a partner might still be inclined to say, ‘Wait a minute, I know it’s that time of your month again. You’re just being oversensitive,’” Browne points out. Women in relationships with women, who tend to be more understanding of premenstrual change than men, report a more positive experience of the week before their period.

    Researchers have done great, necessary work to understand PMDD, work that should continue. How are people who experience premenstrual distress biologically different from people who don’t? Can we find new, more effective drugs to treat that distress?

    In the meantime, we need to build a better world for people who experience premenstrual distress. Doctors can prescribe medicine, but managers can make accommodations in the workplace. Co-parents can take on more caregiving responsibility. And partners can provide love and support.

    Ciara McLaren

    Source link

  • A Genetic Snapshot Could Predict Preterm Birth

    A Genetic Snapshot Could Predict Preterm Birth

    This article was originally published by Knowable Magazine.

    For expectant parents, pregnancy can be a time filled with joyful anticipation: hearing the beating of a tiny heart, watching the fetus wiggling through the black-and-white blur of an ultrasound, feeling the jostling of a little being in the belly as it swells.

    But for many, pregnancy also comes with serious health issues that can endanger both parent and child. In May, for example, the U.S. Olympic sprinter Tori Bowie died while in labor in her eighth month of pregnancy. Potential factors contributing to her death included complications of preeclampsia, a pregnancy-specific disorder associated with high blood pressure. Preeclampsia occurs in an estimated 4.6 percent of pregnancies globally. Left untreated, it can lead to serious problems such as seizures, coma, and organ damage.

    Preeclampsia and preterm birth are relatively common conditions that can put both the mother and her baby at risk of health issues before and after birth. But doctors don’t have a good way to determine whether an individual will develop one of these complications, says Thomas McElrath, an ob-gyn at Brigham and Women’s Hospital, in Boston. Currently, physicians primarily look to a woman’s prior pregnancies, medical history, and factors such as age and ethnicity to determine her risk. These measures are useful but limited, and may fail to identify problems early enough to enable effective treatment, McElrath says. “They’re not as precise as I think most of us, as clinicians, would really want.”

    That may soon change. Scientists are learning that free-floating bits of genetic material found in a pregnant person’s blood may offer a way to detect complications such as preeclampsia and preterm birth—although some experts caution that it’s too early to determine how useful these tests will be in the clinic. In the meantime, the tests are providing researchers with a new way to unravel the underlying biology of these inscrutable ailments.


    All of us carry bits of our own genetic material—both DNA and its more evanescent cousin, RNA—around in our bloodstreams. During pregnancy, these free-floating fragments, known as cell-free DNA and RNA, are also released from the developing fetus into the mother’s blood, primarily via the placenta. For more than a decade, clinicians have used cell-free DNA from blood to screen the fetus for genetic abnormalities.

    But DNA provides a largely static view of the genetic content within our cells. RNA gives a snapshot of which genes are turned on or off at a specific point in time. Because gene activity varies across cells and over time, researchers realized that they could use RNA to glean a more dynamic view of the changes that occur within the mother’s body during pregnancy. RNA enables scientists to look beyond the fixed genotype to factors that change over the course of pregnancy such as prenatal complications, says Mira Moufarrej, a postdoctoral researcher at Stanford University who co-authored a paper in the 2023 Annual Review of Biomedical Data Science on noninvasive prenatal testing with circulating RNA and DNA.

    To screen for possible complications, scientists have been looking at cell-free RNA in pregnant women’s blood that originates from both mother and child. Some of the earliest studies of this kind emerged in the early 2000s. In 2003, for example, Dennis Lo, a chemical pathologist at the Chinese University of Hong Kong, and his colleagues reported that in a study of 22 pregnant women, a specific RNA released from the placenta was much more abundant during the third trimester in those who had preeclampsia than in those who did not. Over the years, Lo’s group and others have looked at broader changes in RNA during pregnancy in larger groups of people.

    In a 2018 study, Moufarrej, who was then a doctoral student; her adviser Stephen Quake, a biophysicist at Stanford University; and colleagues reported that cell-free RNA could help determine when labor would occur. The researchers recruited 38 pregnant women in the United States known to be at risk of preterm birth, and then drew a blood sample from each. By comparing cell-free RNA in those who eventually delivered prematurely with that in those who gave birth at full term, they were able to identify a set of RNAs that appeared up to two months prior to labor that could pinpoint about 80 percent of premature births.

    That proof-of-concept investigation spurred the researchers to look further and examine whether cell-free RNA could also predict preeclampsia. Other groups had previously reported RNA-based signatures of preeclampsia—in 2020, for instance, scientists working with the California-based biotech company Illumina reported dozens of RNA transcripts that were unique to a small cohort of pregnant women with the condition. But Moufarrej, Quake, and their colleagues wanted to track RNA changes throughout pregnancy to see whether it might be possible to identify people at risk of preeclampsia during early pregnancy, before symptoms began.

    In a study published in 2022, the researchers recruited several dozen mothers at heightened risk of preeclampsia and drew blood from them four times: at or before 12 weeks, in weeks 13 to 20, at or after 23 weeks, and after birth. Afterward, the researchers compared cell-free RNA for women who indeed developed preeclampsia against that of those who did not. The team identified RNAs corresponding to 544 genes whose activity differed in those who developed preeclampsia and those who did not. (The study did not differentiate between maternal and fetal RNA, but because the majority of cell-free RNA in a pregnant person’s blood is their own, Moufarrej says that most of these RNAs are likely maternal in origin.)

    Then, using a computer algorithm, the researchers developed a test based on 18 genes measured prior to 16 weeks of pregnancy that could be used to predict a woman’s risk of developing preeclampsia months later. The test correctly identified all of the women who would later develop preeclampsia—and, equally important, all of the women who the test predicted wouldn’t develop preeclampsia did in fact escape the disease. (About a quarter of the women who were predicted to develop preeclampsia did not get the disease.) The same 18-gene panel also correctly predicted most cases of preeclampsia in two other groups totaling 118 women.

    The team also took a closer look at which tissues the RNA of interest originated from. This included the usual suspects, such as the lining of the blood vessels (also known as the endothelium), which scientists already know is associated with preeclampsia, as well as other, more unexpected sources, such as the nervous and muscular systems. The authors note that, in the future, this information could be used both to understand how preeclampsia affects different parts of the body and to assess which organs are at highest risk of damage in a particular patient.

    According to Quake, studies like these from both his team and others are starting to reveal the diversity of changes throughout the body that contribute to pregnancy complications—and providing evidence for something that clinicians and researchers have long suspected: that both preeclampsia and preterm birth are conditions with a range of underlying causes and outcomes. “There are now strong indications that you should be defining multiple subtypes of preeclampsia and preterm birth with molecular signatures,” says Quake. “That could really transform the way physicians approach the disease.”

    Research teams elsewhere are also looking at other pregnancy complications such as reduced fetal growth, which can cause infants to be at higher risk of problems such as low blood sugar and a reduced ability to fight infections. Some of these tests are now being validated in large studies, while others are still in the early days of development.


    RNA-based tests for both preeclampsia and preterm-birth risk are inching their way toward the clinic. Mirvie, a company co-founded by Quake in South San Francisco, is focused on developing both. Last year, the company published a study of a preterm-birth test with hundreds of pregnant individuals as well as one on a preeclampsia test with samples from more than 1,000 women. Both studies had promising results. The company is now in the middle of an even larger study of the preeclampsia test that will include 10,000 pregnancies, Quake says. (Quake and Moufarrej are both shareholders of Mirvie.)

    Cell-free RNA-based tests for preeclampsia are leading the way, says McElrath, likely because preterm birth has more subtypes and more potential causes—including carrying multiples, chronic health conditions such as diabetes, and preeclampsia—which make it a more complicated issue to address. (McElrath is involved in validating Mirvie’s tests; he serves as a scientific adviser to the company and has a financial stake in it.)

    Still, questions about these tests remain. An important next step, says Moufarrej, is determining what’s behind the RNA changes associated with a heightened risk for these pregnancy complications. All of the studies conducted to date have been correlative—linking patterns in RNA with risk—but to provide effective treatment, it will be important to determine the cause of these changes, she adds. Another open question is how important maternal versus fetal RNAs are to determining the risk of pregnancy complications. To date, most studies have not distinguished between these two sources. “This remains an active area of investigation,” McElrath says.

    Erik Sistermans, a human geneticist at Amsterdam UMC, says that although  researchers can learn a lot from cell-free RNA, it’s still too early to judge what the power of these RNA-based tests will be in clinical practice. He notes that he and other researchers are also investigating the possibility of using cell-free DNA to determine the risk of pregnancy complications such as preeclampsia. For example, some groups are looking at chemical modifications to DNA known as epigenetic changes, which occur in response to age, environment, and other factors.

    Yalda Afshar, a maternal- and fetal-medicine physician at UCLA, agrees that it’s still unclear whether these tests will provide benefits not available from existing screening methods such as looking for the presence of risk factors. For these screening tests to truly benefit patients, clinicians will first need to understand the underlying biology of these complications—and have effective treatments to offer patients found to be at risk, she adds. (Afshar is an unpaid consultant for Mirvie.)

    There are also ethical questions to consider. Screening tests provide only an estimate of risk, not a definitive diagnosis, Sistermans notes. Before these tests are rolled out to the public, it will be crucial to consider how best to communicate test results, and what next steps to take for individuals who are identified as being in a high-risk category, he says. For preeclampsia, low-dose aspirin can help prevent or delay its onset, while the hormone progesterone may help prevent some cases of preterm birth. But every additional test added to a prenatal screen makes decisions more complicated and potentially stressful for pregnant women. “You shouldn’t underestimate the amount of anxiety these kinds of tests may cause,” Sistermans says.

    Still, researchers are optimistic about the future of cell-free RNA-based tests. The tests for preeclampsia are already more accurate than currently available tests for the condition, according to McElrath. And if researchers succeed in predicting other complications, he adds, future patients will benefit not just from additional information about their pregnancies, but also from the opportunity to receive more personalized care. “Once we start to see success in early preeclampsia prediction,” McElrath says, “it will quickly spread out from there.”

    Diana Kwon

    Source link